CA2552094A1 - Derives d'amidine pour le traitement de l'amylose - Google Patents

Derives d'amidine pour le traitement de l'amylose Download PDF

Info

Publication number
CA2552094A1
CA2552094A1 CA002552094A CA2552094A CA2552094A1 CA 2552094 A1 CA2552094 A1 CA 2552094A1 CA 002552094 A CA002552094 A CA 002552094A CA 2552094 A CA2552094 A CA 2552094A CA 2552094 A1 CA2552094 A1 CA 2552094A1
Authority
CA
Canada
Prior art keywords
amyloid
compound
group
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002552094A
Other languages
English (en)
Inventor
Xianqi Kong
David Migneault
Xinfu Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health International Ltd
Original Assignee
Neurochem (International) Limited
Xianqi Kong
David Migneault
Xinfu Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem (International) Limited, Xianqi Kong, David Migneault, Xinfu Wu filed Critical Neurochem (International) Limited
Publication of CA2552094A1 publication Critical patent/CA2552094A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002552094A 2004-01-23 2004-01-23 Derives d'amidine pour le traitement de l'amylose Abandoned CA2552094A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2004/000617 WO2005079780A1 (fr) 2004-01-23 2004-01-23 Derives d'amidine pour le traitement de l'amylose

Publications (1)

Publication Number Publication Date
CA2552094A1 true CA2552094A1 (fr) 2005-09-01

Family

ID=34878564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002552094A Abandoned CA2552094A1 (fr) 2004-01-23 2004-01-23 Derives d'amidine pour le traitement de l'amylose

Country Status (5)

Country Link
EP (1) EP1715857A1 (fr)
JP (1) JP2007518786A (fr)
AU (1) AU2004316081A1 (fr)
CA (1) CA2552094A1 (fr)
WO (1) WO2005079780A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2034981A1 (fr) * 2006-03-27 2009-03-18 The Government of the United States of America as Represented by The Department of Health and Human Services Inhibiteurs diamidine de tdp1
JP5160764B2 (ja) 2006-10-13 2013-03-13 全薬工業株式会社 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤
WO2019095046A1 (fr) * 2017-11-16 2019-05-23 Montdorex Inc. Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1658852A (zh) * 2001-08-31 2005-08-24 神经化学（国际）有限公司 用于治疗淀粉样变性的脒衍生物
AU2003251418A1 (en) * 2002-06-07 2003-12-22 Robert J. Chalifour Amidine derivatives for treating amyloidosis

Also Published As

Publication number Publication date
EP1715857A1 (fr) 2006-11-02
WO2005079780A1 (fr) 2005-09-01
JP2007518786A (ja) 2007-07-12
AU2004316081A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
MXPA04001153A (es) Derivados de amidina para tratar la amiloidosis.
US20060167057A1 (en) Compounds for the treatment of CNS and amyloid associated diseases
US7262223B2 (en) Amidine derivatives for treating amyloidosis
AU670232B2 (en) Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US20040248876A1 (en) Methods and compounds for inhibiting amyloid deposits
NO335084B1 (no) Forbindelser og preparater og deres anvendelse for behandling av amyloidrelaterte sykdommer
CA2182731A1 (fr) Compositions et procedes de modulation de l'amyloidose induite par des produits terminaux de glycosylation avancee
MX2007005507A (es) Metodos y composiciones fluoradas para el tratamiento de padecimientos relacionados con amiloides.
PT97770B (pt) Metodo para o tratamento de doenca mental psicotica com uanidinas substituidas tendo elevada afinidade de ligacao ao receptor sigma
US7253306B2 (en) Pharmaceutical drug candidates and methods for preparation thereof
US7145037B2 (en) Adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them
EP4228655A1 (fr) Dérivés de tétracycline pour le traitement de maladies neurodégénératives ou neuroinflammatoires
WO2003063880A1 (fr) Dislocation de l'amyloide insulaire par des composes polycycliques
CA2552094A1 (fr) Derives d'amidine pour le traitement de l'amylose
CA2488493A1 (fr) Derives d'amidine pour le traitement des amyloses
US20080027097A1 (en) Pharmaceutical drug candidates and methods for preparation thereof
Novalbos et al. Effects of dotarizine and flunarizine on chromaffin cell viability and cytosolic Ca2+
US20210268016A1 (en) Methods and compositions for the treatment of amyloid-related disorders
JP2007526228A (ja) アミロイド関連疾患およびてんかん発生関連疾患の治療のための方法および組成物
WO2002024204A2 (fr) Inhibition de l'antiport calcium/sodium mitochondrial
JP2004525906A (ja) アリールｎ−シアノグアニジンおよびこれに関連する方法
NZ258461A (en) Use of 5-substituted ornithine derivatives for preparing medicaments
AU2002325117A1 (en) Amidine derivatives for treating amyloidosis
IL297706A (en) Use of dopamine d3 partial agonists in the treatment of central nervous system diseases

Legal Events

Date Code Title Description
FZDE Dead